
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc. is focused on developing cannabinoid-based formulations for various medical conditions, including Alzheimer's disease, where its investigational drug assets have exhibited potential efficacy in addressing key disease hallmarks such as plaques and tangles. With an updated valuation indicating a significant upside based on a net present value analysis, the stock presents an attractive investment opportunity. Furthermore, the expected release of additional positive data regarding its drug candidates, particularly IGC-AD1, is anticipated to further enhance the stock's appeal and drive future growth.
Bears say
IGC Pharma Inc reported a net loss of $1.6 million for the period, translating to an earnings per share (EPS) of $(0.02), which aligns with prior estimates but indicates a continued struggle to achieve profitability. The company faces significant risks, including balance sheet and liquidity concerns, the uncertain outcome of clinical trials for its product candidates, and challenges in obtaining regulatory approvals and commercializing its products. Coupled with the competitive landscape and evolving investor sentiment towards biotech stocks, these factors contribute to a negative outlook on IGC Pharma's financial stability and future growth potential.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares